Real World Experience of Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis

被引：0
|
作者：
Mulholland, S. A. [1 ]
Al Jbour, K. [1 ]
Steer, H. [2 ]
Gutsche, M. [3 ]
Foley, N. [4 ]
Srivastava, R. [5 ]
Sharp, C. [2 ]
Adamali, H. I. [1 ]
Barratt, S. [1 ]
机构：
[1] Bristol Interstitial Lung Dis Serv, Bristol, Avon, England
[2] Gloucestershire Royal Hosp, Dept Resp Med, Gloucester, England
[3] Cheltenham Gen Hosp, Dept Resp Med, Cheltenham, Glos, England
[4] Royal United Hosp, Dept Resp Med, Bath BA1 3NG, Avon, England
[5] Weston Gen Hosp, Dept Resp Med, Weston Super Mare, England
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2018年 / 197卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A4262
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Tolerability of treatment with pirfenidone or nintedanib for pulmonary fibrosis in the real world
    Ogura, Takashi
    Kitamura, Hideya
    [J]. RESPIROLOGY, 2017, 22 (06) : 1051 - 1052
  • [2] Pirfenidone and Nintedanib for Treatment of Idiopathic Pulmonary Fibrosis
    Sathiyamoorthy, Gayathri
    Sehgal, Sameep
    Ashton, Rendell W.
    [J]. SOUTHERN MEDICAL JOURNAL, 2017, 110 (06) : 393 - 398
  • [3] Real-world safety profiles of pirfenidone and nintedanib in idiopathic pulmonary fibrosis patients
    Fournier, D.
    Jouneau, S.
    Bouzille, G.
    Polard, E.
    Osmont, M. N.
    Scailteux, L. M.
    [J]. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2022, 36 : 77 - 78
  • [4] Real-world safety profiles of pirfenidone and nintedanib in idiopathic pulmonary fibrosis patients
    Fournier, Dorine
    Jouneau, Stephane
    Bouzille, Guillaume
    Polard, Elisabeth
    Osmont, Marie-Noëlle
    Scailteux, Lucie-Marie
    [J]. PULMONARY PHARMACOLOGY & THERAPEUTICS, 2022, 76
  • [5] Pirfenidone In Idiopathic Pulmonary Fibrosis In The Real World
    Song, J.
    Park, J. -H.
    Heo, E.
    Kim, D.
    Chung, H. Hee Soon
    Lee, J-K.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [6] Combination Nintedanib and Pirfenidone for Treatment of Idiopathic Pulmonary Fibrosis Reply
    Vancheri, Carlo
    Kreuter, Michael
    Richeldi, Luca
    Quaresma, Manuel
    Stowasser, Susanne
    Wuyts, Wim A.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 198 (08) : 1105 - 1106
  • [7] Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis
    Flaherty, Kevin R.
    Fell, Charlene D.
    Huggins, J. Terrill
    Nunes, Hilario
    Sussman, Robert
    Valenzuela, Claudia
    Petzinger, Ute
    Stauffer, John L.
    Gilberg, Frank
    Bengus, Monica
    Wijsenbeek, Marlies
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2018, 52 (02)
  • [8] Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis
    Brunnemer, Eva
    Waelscher, Julia
    Tenenbaum, Svenja
    Hausmanns, Julia
    Schulze, Karen
    Seiter, Marianne
    Heussel, Claus Peter
    Warth, Arne
    Herth, Felix J. F.
    Kreuter, Michael
    [J]. RESPIRATION, 2018, 95 (05) : 301 - 309
  • [9] Prescription Of Pirfenidone And Nintedanib For The Treatment Of Idiopathic Pulmonary Fibrosis (ipf): An Academic Center Experience
    Strock, S.
    Nouraie, S. M.
    Huttenhower, D.
    Chen, X.
    Lawson, K.
    Priore, M. Melissa
    Chiarchiaro, J.
    Veraldi, K. L.
    Lindell, K. O.
    Gibson, K. F.
    Kass, D. J.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [10] Real World Experiences: Pirfenidone and Nintedanib are Effective and Well Tolerated Treatments for Idiopathic Pulmonary Fibrosis
    Hughes, Gareth
    Toellner, Hannah
    Morris, Helen
    Leonard, Colm
    Chaudhuri, Nazia
    [J]. JOURNAL OF CLINICAL MEDICINE, 2016, 5 (09)
12345